• California: TTAM Research Institute has won a bankruptcy auction of 23andMe for $305 million. Previously, Regeneron Pharmaceuticals announced plans to purchase 23andMe for $256 million, but the sale process was reopened after TTAM, a nonprofit founded by former 23andMe CEO Anne Wojcicki, bid $305 million. In a press release, 23andMe said TTAM will honor the company's existing policies on data rights, including allowing consumers to delete their data and opt out of research. TTAM will also not sell any data, including in a future bankruptcy, and will add new protections related to privacy and identity theft. "I am thrilled that TTAM Research Institute will be able to continue the mission of 23andMe to help people access, understand and benefit from the human genome," Wojcicki said. "We believe it is critical that individuals are empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish." Currently, the deal is subject to approval by the bankruptcy court, as well as closing conditions. A court hearing on the transaction is scheduled for June 17, and closing will likely occur in the coming weeks. (Herper, STAT+ [subscription required], 6/13; Capoot, CNBC, 6/13)
• Maryland: Earlier this month, FDA launched a new generative AI tool named Elsa, which was designed to "modernize agency functions," increase efficiencies, and help the agency "better serve the American people." According to Healthcare IT News, Elsa can summarize adverse events for safety profile assessments, increase the speed of label comparisons, and generate code to help create databases for nonclinical applications. Elsa was developed and built within a high-security GovCloud environment and allows FDA staff to access internal documents through a secure platform. "Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee," said Jeremy Walsh, FDA's chief AI officer. "As we learn how employees are using the tool, our development team will be able to add capabilities and grow with the needs of employees and the agency." (Miliard, Healthcare IT News, 6/3)
• New York: Capital Rx, an alternative pharmacy benefit manager and administrator, plans to acquire Amino Health, a care navigation company. According to Capital Rx, the acquisition will allow the company to provide a better member-facing experience to align with its unified claims platform on the back end. "One of the things that we expanded into at the end of last year was medical claim processing, or just one system to process medical and pharmacy claims on the same platform," said Capital Rx CEO AJ Loiacono. "But what we realized is we were lacking a front-end navigation." Under the acquisition, Amino's CEO John Asalone will join Capital Rx as the EVP of Judi Care, the care navigation division. Previously, Asalone served as general manager and SVP of telehealth at GoodRx. (Tong, Fierce Healthcare, 6/11)

Generative artificial intelligence is poised to transform healthcare, with potential applications ranging from near-term to revolutionary. Use this field guide to discover how 11 possible use cases could shape the industry and the role of your organization.